NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
9.78
0.00 (0.00%)
May 12, 2026, 4:00 PM EDT - Market closed
NextCure Employees
NextCure had 40 employees as of December 31, 2025. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
n/a
Profits / Employee
-$1,366,600
Market Cap
35.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 40 | -3 | -6.98% |
| Dec 31, 2024 | 43 | -39 | -47.56% |
| Dec 31, 2023 | 82 | -17 | -17.17% |
| Dec 31, 2022 | 99 | 12 | 13.79% |
| Dec 31, 2021 | 87 | -3 | -3.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Evaxion | 46 |
| Mereo BioPharma Group | 39 |
| Boundless Bio | 28 |
| Daré Bioscience | 24 |
| INmune Bio | 21 |
| Veru Inc. | 20 |
| RenovoRx | 17 |
NXTC News
- 1 day ago - NextCure initiated with a Buy at Lucid Capital - TheFly
- 5 days ago - NextCure reports Q1 EPS ($1.87), consensus ($2.03) - TheFly
- 5 days ago - NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 8 days ago - NextCure initiates dose optimization portion of SIM0505 study - TheFly
- 8 days ago - NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - GlobeNewsWire
- 21 days ago - NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 - GlobeNewsWire
- 5 weeks ago - NextCure granted Fast Track Designation for SIM0505 by FDA - TheFly
- 5 weeks ago - NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - GlobeNewsWire